BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 15310998)

  • 1. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of testosterone replacement therapy following radical prostatectomy.
    Khera M; Lipshultz LI
    Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK; Oefelein MG
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
    Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
    BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
    J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
    Heaton JP
    Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
    J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
    Gould DC; Feneley MR; Kirby RS
    BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
    Morgentaler A
    J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Testosterone replacement therapy for late-onset hypogonadism after radical prostatectomy: a case report].
    Nakano K; Kiuchi H; Miyagawa Y; Tsujimura A; Nonomura N
    Hinyokika Kiyo; 2014 Aug; 60(8):397-400. PubMed ID: 25179991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen replacement in men undergoing treatment for prostate cancer.
    Rhoden EL; Averbeck MA; Teloken PE
    J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.